<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Anticancer role of andrographolide is well documented </plain></SENT>
<SENT sid="1" pm="."><plain>To find novel potent derivatives with improved cytotoxicity than andrographolide on <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells, two series of di-spiropyrrolidino- and di-spiropyrrolizidino <z:chebi fb="0" ids="31697,38459">oxindole</z:chebi> andrographolide derivatives prepared by cyclo-addition of <z:chebi fb="0" ids="51159">azomethine ylide</z:chebi> along with <z:chebi fb="0" ids="15611">sarcosine</z:chebi> or proline (viz. <z:chebi fb="0" ids="15611">sarcosine</z:chebi> and proline series respectively) and substitution of different functional groups (-<z:chebi fb="1" ids="29438">CH3</z:chebi>, -OCH3 and <z:chebi fb="62" ids="24473">halogens</z:chebi>) were examined for their cytotoxic effect on a panel of six human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines (colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> HCT116 cells, pancreatic <z:mp ids='MP_0002038'>carcinoma</z:mp> MiaPaCa-2 cells, <z:e sem="disease" ids="C0019204" disease_type="Neoplastic Process" abbrv="">hepatocarcinoma</z:e> HepG2 cells, cervical <z:mp ids='MP_0002038'>carcinoma</z:mp> HeLa cells, <z:mp ids='MP_0008714'>lung carcinoma</z:mp> A549 and <z:hpo ids='HP_0002861'>melanoma</z:hpo> A375 cells) </plain></SENT>
<SENT sid="2" pm="."><plain>Except <z:chebi fb="62" ids="24473">halogen</z:chebi> substituted derivatives of proline series (viz </plain></SENT>
<SENT sid="3" pm="."><plain>CY2, CY14 and CY15 for Br, Cl and I substitution respectively), none of the other derivatives showed improved cytotoxicity than andrographolide in the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines examined </plain></SENT>
<SENT sid="4" pm="."><plain>Order of cytotoxicity of the potent compounds is CY2&gt;CY14&gt;CY15&gt;andrographolide </plain></SENT>
<SENT sid="5" pm="."><plain>Higher toxicity was observed in HCT116, MiaPaCa-2 and HepG2 cells </plain></SENT>
<SENT sid="6" pm="."><plain>CY2, induced <z:hpo ids='HP_0011420'>death</z:hpo> of HCT116 (GI50 10.5), MiaPaCa-2 (GI50 11.2) and HepG2 (GI50 16.6) cells were associated with cell rounding, nuclear fragmentation and increased percentage of apoptotic cells, cell cycle arrest at G1 phase, ROS generation, and involvement of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> pathway </plain></SENT>
<SENT sid="7" pm="."><plain>Upregulation of Bax, Bad, p53, caspases-3,-9 and cleaved PARP; downregulation of Bcl-2, cytosolic NF-κB p65, PI3K and p-Akt; translocation of P53/P21, NF-κB p65 were seen in CY2 treated HCT116 cells </plain></SENT>
<SENT sid="8" pm="."><plain>Thus, three halogenated di-spiropyrrolizidino <z:chebi fb="0" ids="31697,38459">oxindole</z:chebi> derivatives of andrographolide are found to be more cytotoxic than andrographolide in some <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="9" pm="."><plain>The most potent derivative, CY2 induced <z:hpo ids='HP_0011420'>death</z:hpo> of the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells involves ROS dependent <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> pathway like andrographolide </plain></SENT>
</text></document>